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Abstract
Background:  Herpes simplex virus type 2 (HSV-2) is a major cofactor of human
immunodeficiency virus type 1 (HIV-1) sexual acquisition and transmission. In the present
study, we investigated whether HIV-1 and HSV-2 may interact at the cellular level by
forming HIV-1 hybrid virions pseudotyped with HSV-2 envelope glycoproteins, as was
previously reported for HSV type 1.
Methods:  We evaluated in vitro the production of HSV-2/HIV-1 pseudotypes in
mononuclear CEM cells and epithelial HT29 and P4P cells. We analyzed the incorporation
into the HIV-1 membrane of HSV-2 gB and gD, two major HSV-2 glycoproteins required
for HSV-2 fusion with the cell membrane, in co-infected cells and in HIV-1-infected P4P cells
transfected by plasmids coding for gB or gD.
Results: We show that HSV-2 and HIV-1 co-replicated in dually infected cells, and gB and
gD were co-localized with gp160. However, HIV-1 particles, produced in HIV-1-infected
cells expressing gB or gD after transfection or HSV-2 superinfection, did not incorporate
either gB or gD in the viral membrane, and did not have the capacity to infect cells normally
non-permissive for HIV-1, such as epithelial cells.
Conclusion:  Our results do not support the hypothesis of HSV-2/HIV-1 pseudotype
formation and involvement in the synergistic genital interactions between HIV-1 and HSV-2.
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Background
Genital infection by herpes simplex virus type 2 (HSV-2)
is considered one of the major cofactors favoring both sex-
ual transmission and acquisition of the human immuno-
deficiency virus type 1 (HIV-1) [1]. This assertion is based
on several criteria as defined by Judith and Wasserheit [2],
including mainly epidemiological evidence, biological
plausibility, and ongoing intervention studies [1,3,4]. The
biological arguments of HSV-2 as a major cofactor of HIV-
1 sexual transmission include: (i) Disruption of the
mucosal integrity secondary to herpetic ulcerations; (ii) In
vivo association between the genital loads of HIV-1 RNA
and HSV-2 DNA in female genital secretions among HSV-
2 asymptomatic and symptomatic shedders [5-7], and
observation of increased genital shedding of HIV reported
in men with genital ulcers caused by HSV-2 [8]; (iii) In
vitro evidence that HIV-1 and HSV-2 synergistically inter-
act [9-13].
It has been recently hypothesized that HIV-1 and HSV-1
may interact at the cellular level by the formation of HIV-
1 hybrid virions pseudotyped with herpes simplex virus
type 1 (HSV-1) envelope glycoproteins [14,15]. Thus, two
independant studies showed that cell-free culture super-
natant from HIV-1 and HSV-1 dually infected lymphocyte
cell lines was able to induce HIV-1 productive infection in
cells normally resistant to HIV-1 infection, leading to the
proposal that HIV-1 particles may acquire HSV-1 glyco-
proteins through budding at the cell surface [14,15]. Such
pseudotyped HIV-1 virions acquired new phenotypic
properties with a larger cell tropism. Especially, this
would allow the infection of normally non permissive
cells by fusion of the viral envelope with the cell mem-
brane by a mechanism depending on HSV-1 proteins.
Such hybrid virions could have a modified, likely
increased tropism for target cells within the genital
mucosa. In vivo observations obtained by electron micro-
sopy from herpetic skin lesions showed that CD4 negative
epidermal keratinocytes contained HIV-1 and HSV-1 par-
ticles, supporting the hypothesis of the presence of HIV-1
pseudotyped virions [16].
The interactions between HSV-2 and HIV-1 at the cellular
level have been poorly analyzed, and the formation of
pseudotyped particles between the two viruses has not
been yet evaluated. The aim of the present study was to
extend the previous preliminary reports on HSV-1/HIV-1
pseudotype production, to HSV-2 using a variety of epi-
thelial and mononuclear cell lines, and to analyze the
incorporation into the HIV-1 membrane of gB and gD,
two major HSV-2 glycoproteins required for HSV-2 fusion
with the cell membrane.
Results
Colocalization of HSV-2 gB and gD with gp160 in co-
infected or transfected cells
Prior evaluating the potential formation of pseuotyped
particles, we first analyzed at the cellular level the co-
expression of gB and gp160, or gD and gp160, in HIV-1
infected P4P cells superinfected by HSV-2, and in HIV-1-
infected P4P cells transfected by plasmids coding for gB or
gD, by using confocal microscopy. Our observations con-
firm that P4P cells exposed to both HIV-1 and HSV-2 can
be co-infected and coreplicate the two viruses, since we
can detect in the same cell glycoproteins from both
viruses. HIV-1 P4P cells transfected with plasmids coding
for gB or gD also express both the HSV-2 glycoprotein and
gp160 (Figure 1). In addition, as shown in Figure 1, the
superposition of fluorescence signals indicates that gB and
gD may co-localize with HIV-1 gp160 in both co-infected
and transfected P4P cells. The pattern of staining in single
infections with either HIV-1 or HSV-2 was the same as that
observed in co-infected cells (not shown).
CEM cells are susceptible to HSV-2 and HIV-1 co-infection
Prior HSV-1 infection of CEM cells has been shown to
result in a delay of HIV-1 production, due to cell growth
inhibition and apoptosis, while HSV-1 superinfection of
HIV-infected CEM cells promoted HIV expression [17].
We have therefore focused our analysis on this latter con-
dition.
CEM cells infected by HIV-1NDK strain were superin-
fected by HSV-1 or HSV-2 at a multiplicity of infection
(MOI) of 0.01, 0.1 or 1 pfu/cell for 72 h. Every each 24
hours, culture supernatant was collected for viral quantifi-
cations by real time PCR, and after washing cells were
reincubated with fresh medium. Our results show that
HSV-1 and HSV-2 did not modify the production of HIV-
1 RNA, and that HIV-1 did not influence either HSV-1 or
HSV-2 replication in CEM cells (Figures 2 and 3). The cell
free supernatants of dually infected CEM cells were then
used for the infection of Vero cells. In the first 48 h, cyto-
pathic effect related to HSV-2 was observed by optical
microscopy (not shown). No HIV-1 p24 antigen was
detected in the supernatant of Vero cells at 24 h or 48 h,
and DNA of the Vero cell pellet contained no HIV-1 pro-
viral DNA as detected by real time PCR (not shown). The
HSV-1 and HIV-1- co-infected CEM cells and HSV-2- and
HIV-1- co-infected CEM cells did not lead to the produc-
tion of HIV-1 virions able to infect cells that are usually
non-permissive.
HIV-1 particles produced from HIV-1 and HSV-2 co-
infected epithelial cells do not infect Vero cells
Intestinal HT29 cells are epithelial cells susceptible to
infection by both R5 and X4 HIV-1 strains [18]. HT29 cells
were infected with HIV-1NDK for 48 h before HSV-2Virology Journal 2007, 4:2 http://www.virologyj.com/content/4/1/2
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superinfection at MOIs of 0.01, 0.1 and 1. HIV-1 produc-
tion was assessed at 24 and 48 h following the infection.
At 24 h, the medium was removed for viral quantification
and was replaced with fresh medium for the 48 hour time-
point. The results depicted in Figure 4 show that HIV-1
production by HT29 cells decreased significantly follow-
ing HSV-2 superinfection at a MOI of 1 pfu after 24 h (P =
0.04). The influence of HSV-2 at a MOI of 1 pfu on the
decrease of HIV replication was more pronounced 24
hours later. In contrast, lower HSV-2 inoculum (0,1 and
0.01 pfu) did not seem to inhibit HIV-1 production in a
48 h delay. Supernatants of HIV-1 and HSV-2 dually
infected HT29 cells collected at 24 and 48 h did not lead
to HIV-1 infection of Vero cells as determined by detec-
tion of proviral DNA, while HSV-2 replication was con-
firmed by the detection of typical cytopathic effect (not
shown).
P4P cells, derived from the endometrial epithelium, were
also infected in the same conditions as those used for
HT29 cells. The rate of HIV-1 infection of P4P cells was
around 50%, as determined by the ratio of HIV-1 DNA
and albumin levels, suggesting that any viral superinfec-
tion would probably produce dually infected cells. As
shown in Figure 5, superinfection by HSV-2 did not signif-
icantly influence HIV-1 production in P4P cells. The cul-
ture supernatants collected 24 and 48 h after HSV-2
superinfection were used to infect Vero cells. After 48 h of
infection, no HIV-1 proviral DNA was detected in the cell
pellet, while HSV-2 production was confirmed by the
Co-staining of HSV-2 gB or gD with HIV-1 gp160 Figure 1
Co-staining of HSV-2 gB or gD with HIV-1 gp160. HIV-1 infected P4P cells were either superinfected by HSV-2 (A-F) or 
transfected by a plasmid coding for gB (G-I) or gD (J-L). Cells were stained by immunofluorescence for the co-detection of 
gp160 and gB (A-C, G-I) or gp160 and gD (D-F, J-L), using human polyclonal anti-gp160 followed by FITC-labelled F(ab')2 rabbit 
anti-human IgG giving a green staining for HIV-1 gp160 and mouse Mabs against gB or gD followed by a TRITC-labelled rabbit 
anti-mouse IgG giving a red staining for HSV-2 gB or HSV-2 gD.Virology Journal 2007, 4:2 http://www.virologyj.com/content/4/1/2
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HSV-1 and HSV-2 replication in CEM cells co-infected by HIV-1 Figure 3
HSV-1 and HSV-2 replication in CEM cells co-infected by HIV-1. HSV-1 (A) and HSV-2 (B) viral load, expressed in 
log10 copies/ml, has been determined in the supernatant of CEM cells infected by HSV-1 or HSV-2 at an MOI of 1 (dark grey), 
0.1 (light grey) and 0.01 (white) and in HIV positive CEM cells superinfected by HSV-1 or HSV-2 at an MOI of 1 (dotted dark 
grey), 0.1 (dotted light grey) and 0.01 (dotted white) for up to 72 h.
HIV-1 replication in HIV-1 infecetd CEM cells co-infected by HSV-1 or HSV-2 Figure 2
HIV-1 replication in HIV-1 infecetd CEM cells co-infected by HSV-1 or HSV-2. HIV-1 RNA has been quantified in 
the supernatant of CEM cells every 24 h up to 72 h following superinfection by HSV-1 (A) or HSV-2 (B) at an MOI of 1 (dark 
grey), 0.1 (light grey) and 0.01 (white). Cells not superinfected are represented in black. Values are expressed in log10 copies/
ml. Data are representative of three independent experiments.Virology Journal 2007, 4:2 http://www.virologyj.com/content/4/1/2
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detection of HSV-2 DNA in the supernatant (not shown).
Co-infected P4P cells did not produce HIV-1 particles able
to infect Vero cells. To check the infectiousness of HIV par-
ticles produced in the supernatant of co-infected P4P cells,
we tested 24 and 48 h culture supernatants from dually
HIV-1 and HSV-2 infected P4P cells on uninfected P4P
cells for HIV-1 replication. As expected, these superna-
tants induced HIV productive infection at 24 hours (not
shown), thus confirming that supernatants recovered after
co-infection of P4P cells contained infectious HIV-1 parti-
cles.
Similar results were observed for both epithelial cell lines
with R5-tropic strains HIV Ba-L and HIV JR-CSF (not
shown). Thus co-infection of intestinal or endometrial
epithelial cells with HIV-1 and HSV-2 did not lead to the
production of HIV-1 virions with the ability to infect cells
naturally non-permissive for HIV-1.
HIV-1 particles produced from P4P cells expressing HSV-2 
gB or gD
In order to avoid the necrosis and apoptosis of epithelial
cells consequent to HSV-2 infection, we transfected HIV-1
NDK-infected P4P cells with plasmids coding for gB and
gD, which are major glycoproteins involved in fusion of
the HSV-2 envelope with the plasma membrane. Culture
supernatants obtained 48 h following the transfection
were used to infect Vero cells for 24 h. Cell DNA was then
extracted, and tested for HIV-1 DNA. Proviral HIV-1 DNA
was never detected, suggesting that the expression of gB
and gD in HIV-1 infected P4P cells did not modify the
phenotype of HIV-1 viral particles such that they could
infect Vero cells.
Viral capture assay
In order to assess weteher the colocalization of HSV-2 and
HIV glycoproteins can lead to the incorporation of the
former into the HIV-1 envelope, we carried out a viral cap-
ture assay. Supernatants of HSV-2 and HIV-1 dually
infected P4P and CEM cells and of P4P cells infected by
HIV-1 then transfected with plasmids coding for gB or gD
were first incubated with mouse antibody to gB or gD and
biotin-labeled anti-mouse antibody and second with
streptavidin microbeads to capture viral particles bearing
gB or gD glycoproteins. The positive control capture of
HIV-1 particles was assessed by anti-human CD44. Bound
viruses were further tested for the detection of HIV-1 RNA
and HSV-2 DNA. Capture assays with gB or gD specific
antibodies were able to bind HSV-2 virions (Figure 6). No
HIV-1 RNA was detected, either from dually infected cells
or from gB or gD transfected HIV-1 positive cells, suggest-
ing that HIV-1 particles did not acquire gB or gD glycopro-
teins during budding (Figure 6).
Discussion
Sexual transmission of HIV-1 is suspected to be increased
when HSV-2 is shed in the genital tract of dually HIV-1-
and HSV-2-infected individuals [19,20]. HSV-2 may
increase the infectiousness of HIV-infected subjects, by
increasing genital HIV load during an HSV-2 genital recur-
rence [5-8] through the transactivation of HIV-1 LTR by
HIV-1 expression in dually HIV-1 and HSV-2 infected P4P  cells Figure 5
HIV-1 expression in dually HIV-1 and HSV-2 infected 
P4P cells. HIV-1 production in HIV-1 infected P4P cells 24 h 
and 48 h after HSV-2 superinfection at the MOI of 1 (dark 
grey), 0.1 (light grey) and 0.01 (white). Values of HIV-1 RNA 
loads, expressed in log10 copies/ml, are the mean of three 
independent experiments. Control HIV-1 infected HT29 cells 
not superinfected by HSV-2 are represented in black.
HIV-1 expression in dually HIV-1 and HSV-2 infected HT29  cells Figure 4
HIV-1 expression in dually HIV-1 and HSV-2 infected 
HT29 cells. HIV-1 production in infected HT29 cells 24 h 
and 48 h after HSV-2 superinfection at the MOI of 1 (dark 
grey), 0.1 (light grey) and 0.01 (white). Values, expressed in 
pg/ml of p24 Ag, are the mean of three independent experi-
ments. Control HIV-1 infected HT29 cells not superinfected 
by HSV-2 are represented in black.Virology Journal 2007, 4:2 http://www.virologyj.com/content/4/1/2
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interaction with HSV proteins (ICPO, ICP4) or the pro-
duction of pro-inflammatory chemokines known to
enhance HIV-1 replication [9,10]. The recruitment of acti-
vated CD4+ cells [12]that markedly upregulate HIV repli-
cation in HSV-infected lesions [13] may also account for
the high titer of HIV in genital HSV lesions. Other mecha-
nisms increasing the infectiousness of HIV by HSV-2 may
be hypothesized. HIV-1 has been reported to undergo
pseudotype formation in vitro when cells are coinfected
with HIV-1 and other enveloped viruses by acquiring in
the HIV-1 envelope proteins of the co-infecting virus,
including human T lymphotropic virus type 1 [21,22],
HIV-2 [23], endogenous murine retroviruses [24-26],
vesicular stomatitis virus [15], and HSV-1 [14,15]. Such
pseudotype formation results in altered cell tropism for
the next round of infection [21,22]. Pseudotype forma-
Viral capture assay Figure 6
Viral capture assay. HIV-1 and HSV-2 capture by antibodies targeted against cell surface CD44 antigen or HSV-2 gB or gD in 
HIV-1- and HSV-2 dually infected P4P cells (A), CEM cells (B) and HIV-1-infected P4P cells transfected by gB or gD (C). Levels 
of captured virus were determined by HIV-1 RNA (open square) and HSV-2 DNA (bold square) quantification by real time 
PCR and compared to capture by a negative control antibody (biotin labeled anti-mouse) to derive fold-over background val-
ues. Data are representative of three independent experiments.Virology Journal 2007, 4:2 http://www.virologyj.com/content/4/1/2
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tion between HIV-1 and HSV-2 could have an impact on
sexual transmission by facilitating HIV-1 epithelial cell
infection within the genital mucosa.
In the present study, we investigated whether HIV-1 and
HSV-2 can interact at the cellular level by forming HIV-1
hybrid virions pseudotyped with HSV-2 envelope glyco-
proteins, as was previously reported for HSV-1 [14,15].
We report that HIV-1 produced from HIV-1 and HSV-2 co-
infected mononuclear cells and epithelial cells releasing
high titers of both HIV-1 and HSV-2 does not acquire an
increased tropism to naturally non-permissive cells. We
also find no evidence of incorporation into the HIV-1
envelope of gB or gD, which are essential for the binding
and entry of HSV-2 [27,28]. In order to avoid the deleteri-
ous cytopathic effects of HSV-2 infection, we used plas-
mids coding for gB and gD. Despite microscopic
observations of transfected cells expressing both gp160
and gB or gD and a co-localization of HIV-1 envelope pro-
teins and HSV-2 glycoproteins, HIV-1 virions did not
acquire either gB or gD. We cannot completely exclude the
formation of HIV-1 pseudotypes by the incorporation of
other HSV-2 proteins in the HIV-1 viral membrane. How-
ever, our observations demonstrate that no significant
level of surface viral proteins involved in HSV-2 cell entry
was incorporated, since no HSV-2 tropism was detected in
HIV-1 particles. Nor can we exclude pseudotype forma-
tion by the integration of HIV-1 genes into the HSV-2
genome or HSV-2 genes into the HIV-1 genome, as was
described in chickens with the Marek disease herpesvirus
and the reticuloendotheliosis lentivirus, which can both
induce T lymphomas in chickens and often coexist in the
same animal [29,30]. However such hybrid virions do not
acquire a modified cell tropism [29,30]. We observed par-
tial colocalization of gp160 with gB and gD at the plasma
membrane level of co-infected cells and HIV-1-infected
P4P cells transfected with a plasmid coding for gB or gD.
Such slight co-localization may be explained by the major
intracellular expression of gB in early endosomes [31] and
that the final HSV-2 envelope is thought to be acquired in
the trans-Golgi network [28,32] while gp120 is preferen-
tially expressed at the cell surface [33,34]. In addition, the
long cytoplasmic domain of gB with 112 amino acids
could be sterically inhibitory to be incorporated in a ret-
roviral particle [35-38]. These features are consistent with
the lack of gB and gD incorporation into the HIV-1 enve-
lope.
Other studies analyzing interactions between HIV and
herpesviruses did not provide evidence for the formation
of HIV-1 pseudotypes [40]. Similarly, Van Kuyk and col-
leagues have reported that HIV-1 obtained from EBV pro-
ductively infected lymphobastoid cell lines did not
acquire the EBV tropism [41]. Toth and colleagues were
unable to detect HIV-1/HCMV pseudotypes in superna-
tant fluids from dually infected syncytiotrophoblasts [40].
Our observations contrast with previous reports on HIV-
1/HSV-1 pseudotype formation [14,15]. Thus, cell-free
culture supernatant from dually infected lymphocyte cell
lines was able to induce HIV productive infection in cells
normally resistant to HIV infection, but there was no
direct evidence for incorporation of HSV-1 proteins into
the HIV-1 envelope [14,15]. Zhu et al reported the co-
infection of HIV-producing H9 cells with HSV-1 tsJ12, a
temperature sensitive mutant of HSV-1 [15]. Inoculation
of HeLa cells with supernatant from the coinfected H9
cells resulted in HIV production, which was not seen with
supernatant from H9 cells infected only with HIV-1. How-
ever, the level of p24 antigen from H9 cells, which could
be higher in co-infected H9 cells as a consequence of HIV
transactivation by HSV, was not determined before inocu-
lation of Hela cells. Calistri et al have used HIV-1IIIB pro-
duced in H9 cells and HSV-1 to co-infect CEM cells and
CD4- Vero cells with the aim of evaluating pseudotype
formation [14]. High production of HIV was observed
when Vero cells were infected with the CEMHSV/HIVcell-free
supernatant. However, the levels of HIV replication in
CEMHSV/HIV and in control CEMHIV cell-free supernatants
before Vero infection, and those in Vero supernatant
infected with the CEMHIV cell-free supernatants were not
mentioned. In addition, HIV-1 proviral DNA was detected
in Vero cells infected by the CEMHSV/HIVcell-free superna-
tant, but the negative control consisted of Vero cells
infected with supernatant of H9 cells chronically infected
by HIV-1, instead of Vero cells infected with CEMHIV cell-
free supernatants. Prior HSV-1 infection of CEM cells has
been shown to result in a delay of HIV-1 production, due
to cell growth inhibition and apoptosis [17]. Thus we can-
not exclude a significant release of HIV-1 proviral DNA in
CEMHSV/HIVsupernantant, leading to the false positive
detection of HIV-1 proviral DNA in Vero cells.
In conclusion, we find no evidence of in vitro HIV-1/HSV-
2 pseudotype formation in mononuclear cells or in epi-
thelial cells. These findings suggest that the existence of
HIV-1/HSV-2 pseudotype formation in the genital tract of
HIV-1- and HSV-2- co-infected individuals is unlikely, and
that genital HIV-1 particles highly produced under the
influence of HSV-2 genital replication, as observed in
HIV-1- and HSV-2- coinfected women, do not acquire
properties of an epithelial cell-tropic virus, such as HSV.
Finally, the synergistic interactions between HIV-1 and
HSV-2 at the genital level more likely results in increased
genital inoculum of both viruses, rather than in pheno-
type changes of genital HIV-1.Virology Journal 2007, 4:2 http://www.virologyj.com/content/4/1/2
Page 8 of 10
(page number not for citation purposes)
Materials and methods
Cells, viruses, and antibodies
P4P cells were kindly provided by Florence Damond. P4P
cells are adherent HeLa cells transfected by plasmids cod-
ing for CD4 and CCR5 (Barin et al, 2004) and allow infec-
tion by both X4 and R5 viruses. P4P cells were grown in
Dulbecco modified Eagle medium (DMEM) supple-
mented with 10% fetal bovine serum (FBS), 500 mg/mL
G418, and 100 mg/mL hygromycin B and antibiotics
(Penicillin 100 U/ml and streptomycin 100 µg/ml (PS)).
Vero cells (African green monkey kidney cells) were
grown in DMEM supplemented with 10% FBS and PS.
CEM-SS cells were grown in RPMI-1640 medium supple-
mented with 10% FBS and PS.
HSV-2 strain VR734 was obtained from the American
Type Culture Collection (ATCC) (Manassas, VA), HSV-1
MacIntyre Strain was purchased from Advanced Biotech-
nologies Inc (Columbia, MA), and propagation and titer
determination were carried out on Vero cells.
Primary R5-tropic HIV Ba-L, HIV JR-CSF, and X4-tropic
HIV NDK were a gift from Pr. F. Barre'-Sinoussi (Institut
Pasteur, Paris, France). HIV Ba-L and HIV JR-CSF were
produced in primary macrophages; HIV NDK was pro-
duced on IL-2-activated peripheral blood lymphocytes.
Viral titre was measured by HIV-1 p24 antigen quantifica-
tion.
Mouse anti-gB and anti-gD monoclonal antibodies
(Mabs) were obtained from Serotec (Oxford, UK) and
Advanced Biotechnologies Incorporated, respectively.
Purified human polyclonal anti-gp160 IgG was described
previously [39]. FITC-labeled F(ab')2 goat anti-human
IgG, FITC-labeled F(ab')2 rabbit anti-human IgG and
TRITC-labelled rabbit anti-mouse IgG were purchased
from Jackson Immunoresearch (Cambridgeshire, UK)
and Molecular Probes (Cergy Pontoise, France), respec-
tively.
Plasmids
Plasmids pMM245 and pMM346, coding for HSV-2 gB
and gD respectively, were described previously [40].
Infection assay
P4P and HT29 cells in 12-well plates were infected with 5
ng/ml p24 HIV-1BaL, HIV-1JR-CSF, and HIV-1NDK for 3
h at 37°C and CEM cells were infected with 1 ng/105 cells
of p24 HIV-1BaL, HIV-1JR-CSF, and HIV-1NDK. The cells
were washed, and were then either cultured for 48 h
before superinfection with 1, 0.1 or 0.01 plaque forming
unit (pfu)/cell of HSV-2 or transfected with the plasmids
pMM245 and pMM346 and cultured for 48 additional
hours.
Vero cells in 24-well plates were incubated for 3 h at 37°C
with culture supernatants of CEM cells, HT29 cells and
P4P cells. After extensive washing, Vero cells were cultured
for 24 to 48 h. Supernatants were frozen at -80°C until
subsequent analyses and cells were then washed, before
the nucleic acid extraction of the cell pellet for the detec-
tion of proviral DNA.
Transfection assay
The transfection assay was performed using 1 µg of plas-
mid with the transfection agent Fugene® (Roche Applied
Science, Meylan, France). The protein expression was
assessed 48 h following the transfection by intracellular
staining as described below.
Intracellular staining of HSV-2 gB and gD and HIV-1 gp-
160
Cells were washed, fixed with paraformaldehyde (4% in
phosphate-buffered saline [PBS]) for 10 min at 4°C
before permeabilization in PBS with 0.5% Triton X-100
and 10% sucrose at room temperature. After several
washes with PBS, cells were incubated for 30 min with
human anti-gp160 IgG, or with mouse anti-gB or anti-gD
Mabs diluted in PBS with 1% bovine serum albumin.
FITC-labeled F(ab')2 rabbit anti-human IgG and TRITC-
labelled rabbit anti-mouse IgG were further added at a
dilution of 1/50 for 30 min at room temperature. The cov-
erslips were mounted in Mowiol (Sigma, St. Louis, Mo.)
and observed by confocal microscopy. Observations were
made by sequential acquisition with a Zeiss LSM510 Sys-
tem, mounted on an Axiovert 100 M optical microscope
(Carl Zeiss AG, Oberkochen, Germany), using a plana-
pochromat x63, 1.4 numerical aperture oil immersion
objective. Optical sections were acquired, each one with
an image resolution of 512 × 512 pixels.
Viral capture assay
To assess the incorporation of HSV-2 envelope glycopro-
teins into the HIV-1 membrane, we carried out a viral cap-
ture assay to bind viruses bearing gB or gD as follows.
HIV-1, HSV-2, and mixture of HIV-1 and HSV-2 virions,
produced in gB- or gD-expressing P4P cells (200 µl), were
incubated first with 1 µg of mouse anti-gB or mouse anti-
gD and second with 1 µg of anti-mouse biotinylated anti-
body (Sigma-Aldrich, Lyon, France) for 30 min at room
temperature to bind viruses bearing HSV-2 glycoproteins.
Similarly, to bind HIV-1 paricles, supernatants were incu-
bated with mouse anti -human CD44 (BD Biosciences, Le
Pont de Claix, France) and with 1 µg of anti-mouse bioti-
nylated antibody (Sigma-Aldrich) as described [41], since
CD44 has been demonstrated to be the most effective host
cell marker for the capture of HIV-1 from patient samples
and culture-derived virus, independent of the origin of the
virus [41]. To each sample were added 25 µl µMACS™
Streptavidin MicroBeads (Miltenyi Biotec, Auburn, CA)Virology Journal 2007, 4:2 http://www.virologyj.com/content/4/1/2
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and the binding reaction was incubated an additional 10
min at room temperature. Antibody-bound viruses were
then captured by magnetic separation according to the
manufacturer's protocol. Briefly, µMACS columns were
placed in the µMACS™ magnetic separator attached to a
magnetic MultiStand. Each column was prepared by
prewetting with 100 µl protein equilibration buffer and
rinsing twice with 100 µl PBS containing 2% fetal bovine
serum (PBS/FBS). The entire volume of the virus capture
reaction mixture (200 µl) was then applied to the column
and allowed to drain completely. The columns were
washed six times with 200 µl volumes of PBS/FBS. Fifty
microliters of an appropriate lysis buffer (see below) were
then added to the column, allowed to stand for 5 min at
room temperature, and then followed by an additional
150 µl of the same buffer. The eluates were then processed
for nucleic acid purification as follows. Nonspecific viral
binding was assessed by adding anti-mouse biotinylated
antibody to virus before capture (negative control).
Nucleic acid purifications
Nucleic acids were extracted with an extraction protocol
on silica column system (High Pure Viral Nucleic Acid kit,
Roche Diagnostics, Mannheim, Germany) according to
the manufacturer's recommendations. Total nucleic acids
were eluted in 100 µl of RNAse- and DNAse-free water.
Detection and quantification of HIV-1 RNA and DNA
HIV-1 RNA and DNA quantification PCR were carried out
by real time using the forward NEC152 (5'-GCCT-
CAATAAAGCTTGCCTTGA-3') and reverse NEC131 (5'-
GGCGCCACTGCTAGAGATTTT-3') primers and the exo-
nuclease probe (5'-FAM-AAGTAGTGTGTGCCCGTCTGT-
TRTKTGACT-TAMRA-3') in the long terminal repeat gene
[42] on the Light cycler instrument 1.5 (Roche Diagnos-
tics) as described [43]. For HIV RNA quantification, the
positive control consisted of culture supernatant of HIV-1
subtype A strain. For HIV DNA quantification, the positive
control consisted of DNA purified from T lymphoblastoid
cell line 8E5 (NIH, ATCC 8993), containing a single copy
of HIV-1 LAV DNA provirus per cell. The level of albumin
DNA copies, quantified by real time PCR as described pre-
viously [44], was used as an endogenous reference to nor-
malize the variations in cell number or DNA extraction.
HIV-1 RNA was expressed in copies/ml, and HIV-1 DNA
proviral load as the number of HIV-1 DNA copies per 106
cells.
Detection and quantification of HSV-2 DNA
HSV-2 DNA was detected and quantified by real time
PCR, using HSV pol F (5' GCTCGAGT-
GCGAAAAAACGTTC 3') and HSV pol R (5' TGCGGTTGA-
TAAACGCGCAGT 3') as primers, and HSV-2 FLU (5'
GCGCACCAGATCCACGCCCTTGATGAGC-FLUOR) and
HSV-2 LCR (5' LC-Red 640-CTTGCCCCCGCAGAT-
GACGCC-phos) as fluorescence labelled probes, as previ-
ously described [45]. The positive control consisted of the
324-bp pcDNA3.1/HisC-ul30hsv plasmid containing the
targeted nucleotides 2660 to 2963 of the UL30 gene [43].
A standard graph of the Ct values was obtained from serial
dilutions (10 to 107 copies) of the plasmid.
Quantification of HIV-1 p24 antigen
Levels of HIV-1 p24 antigen released in culture superna-
tants were determined by a commercial enzyme-linked
immunosorbent assay (ELISA) (INNOTEST® HIV Antigen
mAb, Innogenetics, Lille, France), with a cutoff value of 1
pg/ml.
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